SG Americas Securities LLC Has $4.09 Million Position in Prestige Consumer Healthcare Inc. $PBH

SG Americas Securities LLC lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 20.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 66,325 shares of the company’s stock after selling 17,114 shares during the period. SG Americas Securities LLC’s holdings in Prestige Consumer Healthcare were worth $4,092,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. First Horizon Corp bought a new position in shares of Prestige Consumer Healthcare during the third quarter worth about $32,000. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares during the last quarter. Geneos Wealth Management Inc. increased its position in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. Danske Bank A S acquired a new stake in Prestige Consumer Healthcare during the 3rd quarter valued at approximately $37,000. Finally, Hantz Financial Services Inc. raised its holdings in Prestige Consumer Healthcare by 373.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock worth $43,000 after purchasing an additional 538 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus price target of $76.50.

Prestige Consumer Healthcare Stock Down 9.0%

Shares of NYSE PBH opened at $52.47 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The company has a 50-day moving average price of $64.69 and a 200-day moving average price of $62.92. The stock has a market capitalization of $2.48 billion, a P/E ratio of 13.88, a P/E/G ratio of 1.72 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1 year low of $51.28 and a 1 year high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the prior year, the company earned $1.22 EPS. The company’s revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).